newsfilter
← Latest News
GlobeNewswire·

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British